AR
LXRX icon

Advisory Research’s Lexicon Pharmaceuticals LXRX Stock Holding History

Advisory Research’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-74,907
Closed -$1.23M – 456
2017
Q2 		$1.23M Buy
74,907
+11,484
+18% +$178K 0.02% 291
2017
Q1 		$909K Sell
63,423
-8,269
-12% -$123K 0.01% 328
2016
Q4 		$992K Buy
+71,692
New +$1.15M 0.01% 281

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advisory Research's LXRX Position: Q3 2017 in Review

Advisory Research sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2017, closing a stake of 74,907 shares — an estimated $1.23M sold.

Advisory Research first reported a position in LXRX in Q4 2016 and held it in 3 quarters. The position peaked at $1.23M in Q2 2017. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2017.

  • Advisory Research reported no remaining Lexicon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Advisory Research sold 74,907 Lexicon Pharmaceuticals shares in Q3 2017, an estimated $1.23M.
  • Advisory Research first reported a position in Lexicon Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Advisory Research's Lexicon Pharmaceuticals position peaked at $1.23M in Q2 2017.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2017.

Based on Advisory Research's 13F filing for Q3 2017, filed 14 Nov 2017.